Advertisement
U.S. markets open in 7 hours 21 minutes
  • S&P Futures

    5,211.75
    -3.00 (-0.06%)
     
  • Dow Futures

    39,229.00
    +6.00 (+0.02%)
     
  • Nasdaq Futures

    18,200.00
    -31.50 (-0.17%)
     
  • Russell 2000 Futures

    2,050.40
    +0.60 (+0.03%)
     
  • Crude Oil

    82.47
    -0.25 (-0.30%)
     
  • Gold

    2,160.90
    -3.40 (-0.16%)
     
  • Silver

    25.17
    -0.10 (-0.40%)
     
  • EUR/USD

    1.0867
    -0.0009 (-0.09%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.33
    -0.08 (-0.56%)
     
  • GBP/USD

    1.2704
    -0.0024 (-0.19%)
     
  • USD/JPY

    150.3940
    +1.2960 (+0.87%)
     
  • Bitcoin USD

    65,082.46
    -3,449.65 (-5.03%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    39,890.69
    +150.29 (+0.38%)
     

Why Puma Biotechnology, Inc. (NASDAQ:PBYI) Looks Like A Quality Company

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. By way of learning-by-doing, we'll look at ROE to gain a better understanding of Puma Biotechnology, Inc. (NASDAQ:PBYI).

Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. Put another way, it reveals the company's success at turning shareholder investments into profits.

See our latest analysis for Puma Biotechnology

How To Calculate Return On Equity?

The formula for ROE is:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for Puma Biotechnology is:

44% = US$9.8m ÷ US$22m (Based on the trailing twelve months to September 2022).

The 'return' is the profit over the last twelve months. That means that for every $1 worth of shareholders' equity, the company generated $0.44 in profit.

Does Puma Biotechnology Have A Good Return On Equity?

By comparing a company's ROE with its industry average, we can get a quick measure of how good it is. The limitation of this approach is that some companies are quite different from others, even within the same industry classification. As is clear from the image below, Puma Biotechnology has a better ROE than the average (25%) in the Biotechs industry.

roe
roe

That is a good sign. Bear in mind, a high ROE doesn't always mean superior financial performance. Aside from changes in net income, a high ROE can also be the outcome of high debt relative to equity, which indicates risk. You can see the 6 risks we have identified for Puma Biotechnology by visiting our risks dashboard for free on our platform here.

The Importance Of Debt To Return On Equity

Virtually all companies need money to invest in the business, to grow profits. That cash can come from retained earnings, issuing new shares (equity), or debt. In the first and second cases, the ROE will reflect this use of cash for investment in the business. In the latter case, the debt used for growth will improve returns, but won't affect the total equity. Thus the use of debt can improve ROE, albeit along with extra risk in the case of stormy weather, metaphorically speaking.

Puma Biotechnology's Debt And Its 44% ROE

We think Puma Biotechnology uses a significant amount of debt to maximize its returns, as it has a significantly higher debt to equity ratio of 4.42. While its ROE is no doubt quite impressive, it could give a false impression about the company's returns given that its huge debt could be boosting those returns.

Conclusion

Return on equity is useful for comparing the quality of different businesses. In our books, the highest quality companies have high return on equity, despite low debt. If two companies have around the same level of debt to equity, and one has a higher ROE, I'd generally prefer the one with higher ROE.

But when a business is high quality, the market often bids it up to a price that reflects this. The rate at which profits are likely to grow, relative to the expectations of profit growth reflected in the current price, must be considered, too. So I think it may be worth checking this free report on analyst forecasts for the company.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

Advertisement